Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

sugemalimab × 30 days × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pleural Effusion, Malignant 1

Interventions

Specimen Handling 413 Magnetic Resonance Spectroscopy 332 pembrolizumab 299 Biopsy 231 Carboplatin 228 Cisplatin 191 Cyclophosphamide 177 Nivolumab 172 Gemcitabine 164 Paclitaxel 154 Bevacizumab 127 Radiotherapy 115 atezolizumab 102 fludarabine 101 Docetaxel 98 Dexamethasone 98 venetoclax 94 Oxaliplatin 89 Rituximab 88 durvalumab 86 Fluorouracil 85 Pemetrexed 84 Radiation 80 Doxorubicin 77 Ipilimumab 75 Prednisone 73 Taxes 71 Lenalidomide 70 Leucovorin 68 Capecitabine 68

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06097962 2026-03-20

Safety and Efficacy of NK510 to Treat NSCLC

Base Therapeutics (Shanghai) Co., Ltd.

Phase EARLY_PHASE1 Recruiting

Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡